NCT07269028Completed
Personalised and Gamification-based Decision Aid (DA): a Randomized Controlled Pilot Study About Colorectal Cancer (CRC) Screening
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide, accounting for approximately 903,000 deaths annually. While population-based screening programmes have demonstrated effectiveness in enhancing early detection and reducing mortality, participation rates remain suboptimal. Adherence is influenced by cognitive, psychological, and socioeconomic barriers. This study aimed to assess the impact of a digital decision aid (DA), incorporating personalisation and gamification elements, on informed decision-making and adherence to CRC screening. DA-CRC is a two-arm randomised controlled pilot trial. Individuals born in 1973-1974 living in the area served by the local health authority of Brescia (Northern Italy) who were invited for the first time to participate in the CRC screening programme, were eligible. An invitation letter, including instructions to download the PREVenGO app, was mailed to potential participants. Upon download, participants were randomised to either the intervention or control arm. The intervention app included questionnaires on family history, knowledge of primary and secondary prevention, and locus of control (LoC), as well as gamification and reward features. The control app provided static educational content only. Notifications prompted users to complete follow-up assessments at 3 months (T1) and 6 months (T2), receive prevention information, and attend screening.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 248 (actual)
- First submitted
- 25 Nov 2025
- Start date
- 15 May 2023
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- University of Pavia
- Diseases
- Colorectal cancer
- NCT number
- NCT07269028
What you commit to
- Study type: Interventional
- Participants enrolled: 248
- From 15 May 2023 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Failure to provide informed consent.
Who the study is looking for
- Stable residence within one of the municipalities served by Brescia LHA;
- Ownership of a smartphone (Android or iOS);
- Proficiency in the Italian language;
- Provision of informed consent within the PREVenGO app.
Age in the registry: 50 years to 51 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Agenzia per la Tutela della Salute (ATS) di Brescia Coordinator of this site? Confirm its status | Brescia | Italy | Unknown status |
Related publications
- A Personalised and Gamified Digital Decision Aid for Colorectal Cancer Screening: A Randomised Controlled Pilot Study.Cancer Med · 2026 · PMID 42216438
This page is information, not medical advice. Discuss any trial with your doctor.